Lilly/Incyte pill beats placebo in mid-stage eczema trial – WHTC

Lilly/Incyte pill beats placebo in mid-stage eczema trial
WHTC
The Phase 2 eczema trial found that after 16 weeks, 61 percent of patients on the highest dose of baricitinib and a topical corticosteroid had at least a 50 percent reduction in symptoms, compared to 37 percent of patients treated with just a steroid

and more »

eczema – Google News